Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 35 analyst ratings
Buy
Strong Buy 34%
Buy 26%
Hold 34%
Sell 6%
Strong Sell 0%

Bulls say

Incyte maintains a robust financial outlook due to its strong revenue generation from established products, particularly Jakafi, which is demonstrating solid year-over-year growth of 8% and is anticipated to continue driving revenue as the commercial legacy business remains a crucial asset. The firm's successful launch of Opzelura, showing significant improvements in patients with atopic dermatitis, highlights its potential in dermatology, adding to its diversified pipeline, which includes promising assets like povorcitinib aimed at offsetting future revenue declines from the impending Jakafi patent expiration in 2028. Overall, the combination of steady legacy product performance and advancements in innovative therapies positions Incyte to achieve sustained revenue growth of approximately 5% to 7% moving forward.

Bears say

Incyte's stock faces a negative outlook due to a disappointing pbo-adjusted effect size for its therapies, which fell short of industry benchmarks set by competitive drugs, indicating potential challenges in market differentiation and sales potential. Additionally, concerns over the efficacy and regulatory risks associated with its pipeline products create further uncertainty regarding future revenue growth, particularly as new competitors may emerge. Ultimately, these factors, combined with the company’s history of clinical trial setbacks and potential for dilutive financing, place significant downward pressure on Incyte's financial prospects.

Incyte (INCY) has been analyzed by 35 analysts, with a consensus rating of Buy. 34% of analysts recommend a Strong Buy, 26% recommend Buy, 34% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 35 analysts, Incyte (INCY) has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.